Aditxt Announces the Appointment of Dr. Lauren Chu
Post# of 1418
(Total Views: 334)
Posted On: 06/19/2021 2:04:20 PM
Aditxt Announces the Appointment of Dr. Lauren Chung to its Board of Directors
As an independent director, Dr. Chung brings deep expertise in healthcare investment and corporate development
Aditx Therapeutics, Inc. (“Aditxt”) (Nasdaq: ADTX), a biotech innovation company with a mission to improve the health of the immune system, announced today that Dr. Lauren Chung will join the Aditxt board of directors as an independent director.
“As a new independent director of Aditxt’s board, Dr. Chung brings deep insights spanning global scientific, investment and business communities, and these experiences strongly complement our future growth goals,” said Amro Albanna, co-founder and CEO of Aditxt. “We look forward to working with Dr. Chung as we establish our portfolio of first-in-human clinical studies, launch new high-growth verticals for our AditxtScore TM immune intelligence platform, and explore partnership strategies across the globe.”
Dr. Chung has over 20 years of healthcare investment management, investment banking, and advisory experience, and is currently a venture partner at Yozma Group Korea. She is the founder and CEO of MINLEIGH LLC, which is focused on identifying, evaluating, and partnering with companies for investments and strategic, operational, and commercial opportunities.
Prior to her current roles, Dr. Chung was a managing director in Healthcare Research at WestPark Capital. Previously, she was a co-founder of Tokum Capital Management, a global healthcare fund, which merged with Perella Weinberg Partners. Prior to that, Dr. Chung managed healthcare investment portfolios at institutional investment firms. Earlier in her career, Dr. Chung was a research scientist doing cutting-edge work in neurodegenerative and genetic disorders at Massachusetts General Hospital/Harvard Medical School and Boston Children’s Hospital.
Dr. Chung has published in many leading peer-reviewed scientific journals, and as a current and former director of public and private companies, she brings a valuable perspective for the company’s strategy and operations, as well as extensive scientific insights.
https://m.investorshangout.com/recentnews/ADTX
As an independent director, Dr. Chung brings deep expertise in healthcare investment and corporate development
Aditx Therapeutics, Inc. (“Aditxt”) (Nasdaq: ADTX), a biotech innovation company with a mission to improve the health of the immune system, announced today that Dr. Lauren Chung will join the Aditxt board of directors as an independent director.
“As a new independent director of Aditxt’s board, Dr. Chung brings deep insights spanning global scientific, investment and business communities, and these experiences strongly complement our future growth goals,” said Amro Albanna, co-founder and CEO of Aditxt. “We look forward to working with Dr. Chung as we establish our portfolio of first-in-human clinical studies, launch new high-growth verticals for our AditxtScore TM immune intelligence platform, and explore partnership strategies across the globe.”
Dr. Chung has over 20 years of healthcare investment management, investment banking, and advisory experience, and is currently a venture partner at Yozma Group Korea. She is the founder and CEO of MINLEIGH LLC, which is focused on identifying, evaluating, and partnering with companies for investments and strategic, operational, and commercial opportunities.
Prior to her current roles, Dr. Chung was a managing director in Healthcare Research at WestPark Capital. Previously, she was a co-founder of Tokum Capital Management, a global healthcare fund, which merged with Perella Weinberg Partners. Prior to that, Dr. Chung managed healthcare investment portfolios at institutional investment firms. Earlier in her career, Dr. Chung was a research scientist doing cutting-edge work in neurodegenerative and genetic disorders at Massachusetts General Hospital/Harvard Medical School and Boston Children’s Hospital.
Dr. Chung has published in many leading peer-reviewed scientific journals, and as a current and former director of public and private companies, she brings a valuable perspective for the company’s strategy and operations, as well as extensive scientific insights.
https://m.investorshangout.com/recentnews/ADTX
(0)
(0)Todos Med Ltd. (TOMDF) Stock Research Links
Scroll down for more posts ▼